Published in Cancer Weekly, November 11th, 2003
"This study demonstrates that ONCURA's unique third-generation equipment is safe, well tolerated, and minimally invasive, with excellent cancer control. Our ongoing multicenter trial will continue to investigate the long-term efficacy of this technique," said Arie Beldegrun, professor of urology, chief of urologic oncology at the David Geffen School of Medicine at UCLA, Los Angeles, California, and the lead investigator of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.